ALXN1210: Preliminary Phase I/II data

Preliminary data from 13 patients with PNH in a 24-week, open-label, dose-escalation, international Phase I/II trial showed

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE